GO:0160193 L-lactate dehydrogenase inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0160193 defines a molecular function: binding to and stopping, preventing, or reducing the activity of L-lactate dehydrogenase (LDH).
• L-lactate dehydrogenase catalyzes the interconversion of pyruvate and L-lactate, a critical step in glycolysis and cellular metabolism.
• Inhibitors of LDH, such as gossypol and small molecules like LDHA inhibitors, have been explored for cancer therapy and fibrosis.
• The term is distinct from enzyme regulators that act on other dehydrogenases; it specifically targets L-lactate dehydrogenase.
• Research on LDH inhibitors often employs cell-based phenotypic screening, structural biology, and biochemical assays.
• Understanding this activity is relevant to cancer metabolism, stem cell activation, and radiation-induced fibrosis.
Description
L-lactate dehydrogenase inhibitor activity (GO:0160193) is a molecular function that describes the binding of a molecule to L-lactate dehydrogenase (LDH) and the subsequent reduction or cessation of its enzymatic activity. LDH is a key enzyme in anaerobic glycolysis, catalyzing the conversion of pyruvate to lactate and regenerating NAD+ from NADH. This activity is fundamental to cellular energy metabolism and has been implicated in various physiological and pathological processes, including cancer, stem cell activation, and fibrosis. Researchers study LDH inhibitors to modulate metabolic pathways and to develop therapeutic strategies. For example, inhibition of LDH activity has been proposed as an approach to cancer therapy, as many cancer cells rely on glycolysis for energy production. Additionally, LDH inhibitors like gossypol have been shown to inhibit radiation-induced pulmonary fibrosis in preclinical models. The molecular function GO:0160193 encompasses any protein or chemical that directly binds and inhibits LDH, thereby affecting downstream metabolic and signaling events. This term is distinct from other enzyme inhibitor activities because it specifically targets L-lactate dehydrogenase, a well-characterized enzyme with multiple isoforms. Understanding this function is crucial for researchers investigating metabolic regulation, drug discovery, and disease mechanisms.
L-lactate dehydrogenase inhibitor activity At A Glance
| GO ID | GO:0160193 |
|---|---|
| GO term | L-lactate dehydrogenase inhibitor activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to and inhibiting the enzymatic activity of L-lactate dehydrogenase |
| Definition source | QuickGO |
| Related enzyme | L-lactate dehydrogenase (LDH), including isoforms LDHA and LDHB |
| Relevance | Cancer metabolism, fibrosis, stem cell biology, drug discovery |
What Is GO:0160193?
According to the Gene Ontology, GO:0160193 (L-lactate dehydrogenase inhibitor activity) is defined as the molecular function of binding to and stopping, preventing, or reducing the activity of L-lactate dehydrogenase. This means that a gene product or chemical agent with this activity interacts with LDH and decreases its ability to catalyze the conversion of pyruvate to lactate (or the reverse reaction). The term is classified under molecular_function and does not have synonyms in the QuickGO database. It is important to note that this activity is specific to L-lactate dehydrogenase and not other dehydrogenases.
Why Is L-lactate dehydrogenase inhibitor activity Important in Cell Biology?
L-lactate dehydrogenase inhibitor activity is important because LDH plays a central role in cellular metabolism, and its inhibition can modulate key pathways involved in disease. In cancer, many tumor cells exhibit increased glycolysis and rely on LDH to sustain energy production and biosynthetic precursors; thus, inhibiting LDH is a potential therapeutic strategy. Small molecule inhibitors of LDHA, such as those identified through phenotypic screening, have shown anti-osteosarcoma activity. Gossypol, a natural LDH inhibitor, has been demonstrated to inhibit radiation-induced pulmonary fibrosis in mice. Furthermore, LDH activity is required for hair follicle stem cell activation, indicating a role in tissue regeneration. The study of this molecular function therefore bridges basic metabolism, drug development, and regenerative medicine.
• Provides a target for cancer therapy, as LDH inhibition can selectively affect glycolytic tumor cells.
• Gossypol, an LDH inhibitor, reduces radiation-induced pulmonary fibrosis in preclinical models.
• LDH activity is essential for hair follicle stem cell activation, linking metabolism to tissue regeneration.
• Small molecule LDHA inhibitors show anti-osteosarcoma activity, highlighting therapeutic potential.
• Structural studies of LDHA-gossypol complexes inform rational drug design.
• Orally bioavailable LDHA inhibitors are being developed for pancreatic cancer.
• L-lactate dehydrogenase is found in mitochondria, suggesting broader metabolic roles.
• Measurement of total LDH activity is a standard clinical and research assay.
• Inhibiting LDH can alter cellular redox balance and NAD+ regeneration.
• The term facilitates annotation of gene products that modulate LDH, aiding functional genomics.
Molecular Mechanism of L-lactate dehydrogenase inhibitor activity
Binding of inhibitor to L-lactate dehydrogenase
In simple terms: An inhibitor molecule attaches to the LDH enzyme.
The first step in L-lactate dehydrogenase inhibitor activity is the physical binding of an inhibitor to the LDH enzyme. This binding can occur at the active site or at an allosteric site, depending on the inhibitor. For example, gossypol binds to the NADH-binding site of LDHA, as revealed by structural studies. Small molecule inhibitors identified through phenotypic screening also directly interact with LDHA. The binding affinity and specificity determine the potency of inhibition.
Conformational changes and active site blockade
In simple terms: The inhibitor changes the enzyme's shape or blocks its active site.
Upon binding, inhibitors may induce conformational changes in LDH that prevent substrate (pyruvate or lactate) and cofactor (NADH or NAD+) from accessing the active site. Structural analysis of the LDHA-gossypol complex shows that gossypol occupies the NADH-binding pocket, thereby blocking cofactor binding and catalysis. This mechanism is common among competitive inhibitors of LDH.
Reduction of catalytic activity
In simple terms: The enzyme can no longer convert pyruvate to lactate efficiently.
As a result of inhibitor binding, the catalytic conversion of pyruvate to L-lactate (and the reverse reaction) is reduced. This leads to decreased lactate production and altered NAD+/NADH ratios. Biochemical assays measuring LDH activity in the presence of inhibitors, such as gossypol or small molecules, demonstrate dose-dependent inhibition. The reduction in activity can be quantified using standard LDH activity assays.
Downstream metabolic consequences
In simple terms: Inhibiting LDH affects cellular metabolism and energy production.
Inhibition of LDH activity impacts glycolysis and cellular redox balance. Cancer cells that rely on glycolysis may undergo metabolic stress and reduced proliferation. In stem cells, LDH inhibition can block activation, as shown in hair follicle stem cells. In fibrosis models, LDH inhibition reduces pathological collagen deposition. These downstream effects highlight the physiological relevance of LDH inhibitor activity.
Key Genes Involved in GO:0160193 L-lactate dehydrogenase inhibitor activity
The following genes and proteins are directly involved in or targeted by L-lactate dehydrogenase inhibitor activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDHA | Encodes the muscle isoform of L-lactate dehydrogenase, catalyzing pyruvate to lactate | Primary target of inhibitors; studied in cancer, stem cells, and fibrosis |
| LDHB | Encodes the heart isoform of L-lactate dehydrogenase, catalyzing lactate to pyruvate | Potential target; less studied but relevant in metabolic tissues |
| LDHC | Encodes the testis-specific isoform of L-lactate dehydrogenase | Implicated in spermatogenesis; potential target in reproductive biology |
| SLC16A1 | Monocarboxylate transporter 1 (MCT1), transports lactate | Indirectly related; affects lactate flux and LDH function |
| SLC16A3 | Monocarboxylate transporter 4 (MCT4), exports lactate | Indirectly related; modulates extracellular lactate |
| HIF1A | Hypoxia-inducible factor 1-alpha, upregulates LDHA | Regulates LDH expression; links hypoxia to metabolism |
| MYC | Oncogene that promotes glycolysis and LDHA expression | Drives metabolic reprogramming in cancer |
| PIK3CA | PI3K catalytic subunit, activates AKT and glycolysis | Upstream regulator of LDH expression |
| AKT1 | Serine/threonine kinase, promotes glycolysis | Regulates LDH activity via signaling |
| MTOR | Mechanistic target of rapamycin, controls metabolism | Influences LDH expression and activity |
| TP53 | Tumor suppressor, regulates metabolism | Loss of p53 alters LDH dependence |
| GAPDH | Glycolytic enzyme, produces NADH for LDH | Functional partner in glycolysis |
| PKM | Pyruvate kinase, produces pyruvate for LDH | Upstream of LDH in glycolysis |
| NAD+ | Cofactor for LDH | Essential for catalytic activity; inhibitor binding may compete |
| Gossypol | Natural product inhibitor of LDH | Used in research to inhibit LDH in fibrosis and cancer |
| LDHA inhibitor (small molecule) | Synthetic inhibitor of LDHA | Developed for cancer therapy |
| Atorvastatin | Statin that may affect LDH indirectly | Not a direct inhibitor; included for context |
| Oxamate | Pyruvate analog that inhibits LDH | Classic LDH inhibitor used in research |
How Is L-lactate dehydrogenase inhibitor activity Regulated?
The activity of L-lactate dehydrogenase inhibitors is regulated at multiple levels. The expression of LDH itself is controlled by hypoxia-inducible factors (HIFs) and oncogenes such as MYC, which can influence the efficacy of inhibitors. Additionally, the cellular redox state and NAD+/NADH ratio can modulate inhibitor binding. For example, gossypol competes with NADH for binding to LDHA, so high NADH levels may reduce its inhibitory effect. Furthermore, post-translational modifications of LDH, such as phosphorylation, could alter its sensitivity to inhibitors, though specific modifications are not fully characterized. The development of orally bioavailable LDHA inhibitors for pancreatic cancer highlights the importance of pharmacokinetic regulation. In stem cells, LDH activity is regulated during activation, and inhibitors can block this process.
L-lactate dehydrogenase inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Cancer (osteosarcoma, pancreatic cancer) | Xenograft mouse models, cell lines with LDHA knockout |
| LDHA | Radiation-induced pulmonary fibrosis | Mouse model of thoracic irradiation treated with gossypol |
| LDHA | Hair follicle stem cell activation | Mouse models with conditional LDHA knockout |
| LDHB | Metabolic disorders | Cell lines with LDHB overexpression or knockout |
| LDHC | Male infertility | LDHC knockout mice |
Cancer metabolism and LDH inhibitors
Many cancer cells exhibit the Warburg effect, relying on glycolysis and LDH activity for energy production and biosynthesis. Inhibiting LDH, particularly LDHA, has been proposed as a therapeutic strategy. Small molecule inhibitors of LDHA have shown anti-osteosarcoma activity in cell-based assays. Orally bioavailable LDHA inhibitors are being developed for pancreatic cancer, demonstrating preclinical efficacy. These findings suggest that L-lactate dehydrogenase inhibitor activity is a promising target for cancer therapy.
Radiation-induced pulmonary fibrosis
Gossypol, an LDH inhibitor, has been shown to inhibit radiation-induced pulmonary fibrosis in mice. This suggests that LDH activity contributes to fibrotic processes, and its inhibition may be beneficial in preventing or treating fibrosis. The mechanism may involve reduced lactate production and altered redox signaling in fibroblasts.
Stem cell activation and tissue regeneration
Lactate dehydrogenase activity drives hair follicle stem cell activation, as demonstrated by Flores et al.. Inhibiting LDH could therefore modulate stem cell behavior, with implications for regenerative medicine. This highlights a non-oncological role for LDH inhibitor activity.
Mitochondrial LDH and metabolic disorders
L-lactate dehydrogenase has been found in the inner mitochondrial compartment of pig liver, suggesting additional roles in mitochondrial metabolism. Inhibitors targeting mitochondrial LDH could affect oxidative phosphorylation and may be relevant to metabolic disorders, though this is an emerging area.
From L-lactate dehydrogenase inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDHA affect tumor growth? | LDHA knockout cancer cell lines and xenografts |
| Can a point mutation in LDHA alter inhibitor sensitivity? | CRISPR knock-in of specific LDHA mutations |
| Does LDHA inhibition block stem cell activation? | Conditional LDHA knockout in mouse hair follicle stem cells |
| What is the effect of LDHA overexpression on fibrosis? | LDHA overexpression in fibroblasts followed by radiation |
| Can tagged LDHA be used to study inhibitor binding? | Knock-in of epitope-tagged LDHA |
| Does LDHB compensate for LDHA loss? | Double knockout of LDHA and LDHB |
How to Study the L-lactate dehydrogenase inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LDH activity assay | Enzymatic conversion of NADH to NAD+ | Screening inhibitors, quantifying inhibition |
| Cell viability assay | ATP content or metabolic activity | Assessing anti-cancer effects of LDH inhibitors |
| X-ray crystallography | Three-dimensional structure of LDH-inhibitor complex | Rational drug design |
| Seahorse extracellular flux | Glycolysis and oxidative phosphorylation | Metabolic phenotyping upon LDH inhibition |
| Western blot | Protein expression levels of LDHA/LDHB | Validating knockout or overexpression |
| CRISPR screening | Gene essentiality and resistance | Identifying synthetic lethal interactions with LDH inhibitors |
| Lactate assay | Lactate concentration in medium or lysate | Measuring LDH activity indirectly |
| Immunoprecipitation | Protein-protein interactions | Studying LDH complexes with inhibitors |
Biochemical LDH activity assays
Total LDH activity is measured spectrophotometrically by monitoring the conversion of NADH to NAD+ at 340 nm. This assay is used to assess the inhibitory potency of compounds. It can be performed with purified enzyme or cell lysates.
Cell-based phenotypic screening
High-throughput screening of small molecule libraries can identify LDH inhibitors that affect cancer cell viability or proliferation. This approach led to the identification of human LDHA inhibitors with anti-osteosarcoma activity.
Structural biology (X-ray crystallography)
Co-crystallization of LDH with inhibitors, such as gossypol, reveals the binding mode and guides rational design. Structural data are essential for understanding inhibitor specificity.
Metabolic flux analysis
Measuring lactate production and glucose consumption using Seahorse or NMR can determine the impact of LDH inhibitors on cellular metabolism. This method links inhibitor activity to functional outcomes.
How CRISPR Can Be Used to Study GO:0160193 L-lactate dehydrogenase inhibitor activity
Knockout
CRISPR knockout of LDHA or LDHB can be used to study the consequences of loss of LDH activity. For example, LDHA knockout in cancer cell lines reduces lactate production and inhibits tumor growth. Conditional knockout in mice can reveal tissue-specific roles, such as in hair follicle stem cells.
Point Mutation
Introducing point mutations in the LDHA active site (e.g., replacing catalytic residues) can abolish enzymatic activity and mimic inhibition. Such models help distinguish between catalytic and non-catalytic functions. Point mutations can also confer resistance to specific inhibitors, aiding in target validation.
Knock-in
Knock-in of epitope-tagged LDHA (e.g., FLAG or HA) allows for immunoprecipitation and binding studies with inhibitors. Knock-in of disease-associated mutations can model altered inhibitor sensitivity. This approach is valuable for structural and biochemical studies.
Overexpression
Overexpression of LDHA or LDHB can be achieved by CRISPR activation or lentiviral delivery. Overexpression models are used to study the effects of increased LDH activity on metabolism, fibrosis, and cancer. They can also be used to test whether inhibitors can overcome high enzyme levels.
How EDITGENE Supports L-lactate dehydrogenase inhibitor activity Research
Researchers studying L-lactate dehydrogenase inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to create precise cellular and animal models, enabling functional validation of genes such as LDHA, LDHB, and their regulators.
Contact EDITGENE today to design your custom CRISPR model for L-lactate dehydrogenase inhibitor activity research.
Frequently Asked Questions About L-lactate dehydrogenase inhibitor activity
What is L-lactate dehydrogenase inhibitor activity?
It is a molecular function (GO:0160193) where a molecule binds to and reduces the enzymatic activity of L-lactate dehydrogenase, as defined by the Gene Ontology.
What genes are involved in L-lactate dehydrogenase inhibitor activity?
The primary gene is LDHA, which encodes the LDH enzyme targeted by inhibitors. Other related genes include LDHB, LDHC, and regulators like HIF1A.
How is L-lactate dehydrogenase inhibitor activity measured?
It is typically measured using biochemical assays that monitor NADH oxidation at 340 nm in the presence of LDH and a candidate inhibitor.
What diseases are associated with L-lactate dehydrogenase inhibitor activity?
Cancer, radiation-induced pulmonary fibrosis, and metabolic disorders are associated with LDH activity and its inhibition.
What are examples of L-lactate dehydrogenase inhibitors?
Gossypol is a natural inhibitor, and small molecules like LDHA inhibitors have been developed for cancer therapy.
How does LDH inhibition affect cancer cells?
Inhibiting LDH can reduce glycolysis, induce metabolic stress, and inhibit tumor growth in cancers that rely on lactate production.
Can CRISPR be used to study L-lactate dehydrogenase inhibitor activity?
Yes, CRISPR knockout, knock-in, and point mutation models can be used to validate the role of LDH and its inhibitors in cellular processes.
What is the difference between LDHA and LDHB?
LDHA primarily catalyzes pyruvate to lactate, while LDHB favors the reverse reaction. Both are L-lactate dehydrogenases but have different tissue distributions and kinetics.
Is L-lactate dehydrogenase inhibitor activity a drug target?
Yes, it is considered a promising target for cancer therapy and fibrosis, with several inhibitors in preclinical development.
Where can I find CRISPR models for LDH genes?
EDITGENE provides custom CRISPR knockout, knock-in, point mutation, and overexpression models for LDHA, LDHB, and related genes.
Conclusion
L-lactate dehydrogenase inhibitor activity (GO:0160193) is a well-defined molecular function with significant implications for cancer metabolism, fibrosis, and stem cell biology. The availability of biochemical assays, structural data, and CRISPR models enables researchers to dissect the mechanisms and therapeutic potential of LDH inhibition. As the field advances, targeting LDH activity may yield novel treatments for metabolic diseases and cancer.
References
- 1. Flores A et al.. 2017. Lactate dehydrogenase activity drives hair follicle stem cell activation.. Nat Cell Biol 19(9):1017-1026 PMID: 28812580
- 2. Vanderlinde RE. 1985. Measurement of total lactate dehydrogenase activity.. Ann Clin Lab Sci 15(1):13-31 PMID: 3882046
- 3. Sharma H et al.. 2024. Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer.. Eur J Med Chem 275:116598 PMID: 38925013
- 4. Paventi G et al.. 2017. The occurrence of l-lactate dehydrogenase in the inner mitochondrial compartment of pig liver.. Biochem Biophys Res Commun 489(2):255-261 PMID: 28564593
- 5. Judge JL et al.. 2017. The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Radiation-Induced Pulmonary Fibrosis.. Radiat Res 188(1):35-43 PMID: 28463588
- 6. Wang F et al.. 2020. Identification of human lactate dehydrogenase A inhibitors with anti-osteosarcoma activity through cell-based phenotypic screening.. Bioorg Med Chem Lett 30(4):126909 PMID: 31879209
- 7. Ha MS et al.. 2024. Structural basis of lactate dehydrogenase A-gossypol complex.. Biochem Biophys Res Commun 733:150721 PMID: 39307113
- 8. Fiume L et al.. 2014. Inhibition of lactate dehydrogenase activity as an approach to cancer therapy.. Future Med Chem 6(4):429-45 PMID: 24635523
